Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 176

Sort by

Sort Order Select

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

Blood (2024) 144 (11): 1193–1205.

https://doi.org/10.1182/blood.2024024283

Published: 2024

Includes: Supplemental data

Journal Articles

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Sarah Elitzur, Ruth Shiloh, Jan Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Stephane Ducassou, Nizar Mahlaoui, Marion Strullu, Thomas Lehrnbecher, Kjeld Schmiegelow, Oussama Abla, Liliia Anderzhanova, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Francesco Ceppi, Nicole Bodmer, Triantafyllia Brozou, Luciano Dalla-Pozza, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Sarah K. Tasian, Thai Hoa Tran, Marek Ussowicz, Jose Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Ronit Nirel, Veronique Minard-Colin, Andishe Attarbaschi, Arndt Borkhardt

Blood (2023) 142 (Supplement 1): 520.

https://doi.org/10.1182/blood-2023-179333

Published: 2023

Journal Articles

Independent Prognostic Value of DNA-Based Minimal Residual Disease Assessment in Unselected Population-Based Cohort of Pediatric Acute Myeloid Leukemia

Marketa Zaliova, Jan Zuna, Lucie Winkowska, Iveta Janotova, Justina Skorepova, Julius Lukes, Claus Meyer, Rolf Marschalek, Jiri Domansky, Zbynek Novak, Jan Stary, Lucie Sramkova, Jan Trka

Blood (2023) 142 (Supplement 1): 4327.

https://doi.org/10.1182/blood-2023-179723

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

Blood (2023) 142 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2023-180355

Published: 2023

Journal Articles

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Shunsuke Kimura, Petri Pölönen, Lindsey Montefiori, Kenneth Caldwell, Ilaria Iacobucci, Chelsey Chen, Anthony Brown, Katie Han, Yen-Chun Liu, Yunchao Chang, Zhongshan Cheng, Zhou Yinmei, Chun Shik Park, Sharnise Mitchell, Noemi Reyes, Allen Yeoh, Andishe Attarbaschi, Andrew Moore, Atsushi Manabe, Barbara Buldini, Kean Hui Chiew, Chi Kong Li, Ching-Hon Pui, Chunxu Qu, Daisuke Tomizawa, Elisabeth Paietta, Franco Locatelli, Gabriele Escherich, Gao Qingsong, Hannah Elisa Muhle, Hanne Vibeke Marquart, Hester A. de Groot-Kruseman, Jacob M. Rowe, Jan Stary, Jan Trka, John Kim Choi, Jules P.P. Meijerink, Junko Takita, Katarzyna Pawinska-Wasikowska, Kjeld Schmiegelow, Mariko Eguchi, Martin Schrappe, Martin Zimmermann, Masatoshi Takagi, Melissa Maybury, Michael Svaton, Michaela Reiterova, Michal Kicinski, Motohiro Kato, Orietta Spinelli, Pauline Mazilier, Paul G. Thomas, Riccardo Masetti, Rishi Sury Kotecha, Rob Pieters, Sarah Elitzur, Selina M Luger, Shuhong Shen, Sima Jeha, Steven M. Kornblau, Szymon Skoczen, Takako Miyamura, Tiffaney Vincent, Toshihiko Imamura, Valentino Conter, Yanjing Tang, Zhaohui Gu, Kathryn G. Roberts, David T. Teachey, Kristine R Crews, Cheng Cheng, Jun J. Yang, Hiroto Inaba, Charles G. Mullighan

Blood (2023) 142 (Supplement 1): 845.

https://doi.org/10.1182/blood-2023-178688

Published: 2023

Journal Articles

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H. J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2023) 141 (5): 529–533.

https://doi.org/10.1182/blood.2022017003

Published: 2023

Includes: Supplemental data

Journal Articles

UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia

Blood (2022) 140 (Supplement 1): 1355–1356.

https://doi.org/10.1182/blood-2022-159002

Published: 2022

Journal Articles

BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Blood (2022) 140 (Supplement 1): 9179–9180.

https://doi.org/10.1182/blood-2022-158926

Published: 2022

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

Transient Monosomy 7 Is a Rare Event in Young Children with SAMD9L Syndrome

Blood (2022) 140 (Supplement 1): 8678–8679.

https://doi.org/10.1182/blood-2022-159221

Published: 2022

Journal Articles

Treatment Outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study

Blood (2022) 140 (Supplement 1): 3403–3404.

https://doi.org/10.1182/blood-2022-156731

Published: 2022

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Blood (2022) 139 (12): 1785–1793.

https://doi.org/10.1182/blood.2021012328

Published: 2022

Includes: Supplemental data

Journal Articles

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

Blood (2021) 138 (23): 2441–2445.

https://doi.org/10.1182/blood.2021012781

Published: 2021

Includes: Supplemental data

Journal Articles

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H.J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2021) 138 (Supplement 1): 1314.

https://doi.org/10.1182/blood-2021-152971

Published: 2021

Journal Articles

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2021) 138 (Supplement 1): 2383.

https://doi.org/10.1182/blood-2021-145058

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

Blood (2021) 138 (Supplement 1): 2360.

https://doi.org/10.1182/blood-2021-148041

Published: 2021

NARROW

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Independent Prognostic Value of DNA-Based Minimal Residual Disease Assessment in Unselected Population-Based Cohort of Pediatric Acute Myeloid Leukemia

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia

BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Transient Monosomy 7 Is a Rare Event in Young Children with SAMD9L Syndrome

Treatment Outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Association of unbalanced translocation der(1;7) with germline GATA2 mutations

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only